| imfinzi durvalumab biggest controversy | 1.22 | 1 | 8123 | 38 | 10 |
| imfinzi durvalumab biggest competitor in cost | 1 | 0.6 | 2342 | 45 | 12 |
| imfinzi durvalumab biggest competitor | 1.9 | 0.8 | 6085 | 37 | 55 |
| imfinzi durvalumab biggest challenge | 1.95 | 0.7 | 4081 | 36 | 33 |
| imfinzi durvalumab biggest comparison | 1.59 | 0.1 | 2392 | 37 | 44 |
| imfinzi durvalumab biggest collaboration | 1.81 | 0.8 | 760 | 40 | 74 |
| imfinzi durvalumab biggest clinical trial | 1.36 | 0.3 | 1951 | 41 | 40 |
| imfinzi durvalumab biggest commercial | 1.09 | 0.5 | 75 | 37 | 17 |
| imfinzi durvalumab biggest cost | 1.99 | 0.5 | 7012 | 31 | 36 |
| imfinzi durvalumab biggest company | 1.21 | 0.6 | 9597 | 34 | 71 |
| imfinzi durvalumab biggest customer | 0.65 | 0.6 | 4342 | 35 | 77 |
| durvalumab imfinzi package insert | 1.29 | 0.1 | 5225 | 33 | 24 |
| imfinzi durvalumab side effects | 1.03 | 1 | 5005 | 31 | 34 |
| j code for imfinzi durvalumab | 1.74 | 0.3 | 375 | 29 | 94 |
| imfinzi biggest competitor in clinical trials | 1.15 | 0.6 | 5936 | 45 | 44 |
| cpt code for durvalumab imfinzi | 1.92 | 0.5 | 2548 | 31 | 5 |
| imjudo tremelimumab + imfinzi durvalumab | 0.95 | 0.9 | 3986 | 40 | 18 |
